Table 1.
Characteristics of Patients with BRVO and Healthy Control Participants in This Study
| Variables | BRVO Eyes (n = 70) | Fellow Eyes (n = 70) | Healthy Control Eyes (n = 35) | P (BRVO vs. Fellow) | P (Fellow vs. Control) |
|---|---|---|---|---|---|
| Age (y), mean ± SD | 57.40 ± 9.41 | 56.80 ± 11.45 | NA | 0.80 | |
| Gender (men/women), n | 38/32 | 18/17 | NA | 0.78 | |
| Right eye, n (%) | 42 (60.0) | 42 (60.0) | 16 (45.7) | NA | 0.17 |
| Symptom duration (mo), mean ± SD | 1.71 ± 1.37 | NA | NA | NA | NA |
| IOP (mm Hg), mean ± SD | 14.86 ± 3.42 | 15.40 ± 2.87 | 15.47 ± 2.85 | 0.27 | 0.92 |
| Refractive error (SE, D), mean ± SD | –0.32 ± 1.46 | –0.54 ± 1.57 | –0.24 ± 1.18 | 0.16 | 0.37 |
| Systolic blood pressure (mm Hg), mean ± SD | 133.24 ± 11.62 | 128.24 ± 11.12 | NA | 0.06 | |
| Diastolic blood pressure (mmHg), mean ± SD | 79.30 ± 7.62 | 79.45 ± 5.48 | NA | 0.92 | |
| Occlusion area (ST/IT), n | 50/20 | NA | NA | NA | NA |
| Quadrants measured (ST/IT), n | 20/50 | 20/50 | 9/26 | NA | 0.76 |
| BCVA (logMAR) | 0.68 ± 0.35 | 0.01 ± 0.05 | –0.00 ± 0.01 | <0.01 | 0.20 |
| BCVA (Snellen equivalent), mean (range) | 20/32 (20/400–20/25) | 20/20 (20/25–20/13) | 20/20 (20/20–20/17) | NA | NA |
| VD of SCP (%), mean ± SD | 38.97 ± 4.46 | 51.06 ± 4.08 | 52.62 ± 2.80 | <0.01 | 0.07 |
| VD of DCP (%), mean ± SD | 35.88 ± 5.63 | 48.03 ± 6.56 | 50.24 ± 3.36 | <0.01 | 0.09 |
| FAZ of SCP (mm2), mean ± SD | 0.42 ± 0.17 | 0.36 ± 0.10 | 0.32 ± 0.09 | <0.01 | 0.05 |
| FAZ of DCP (mm2), mean ± SD | 1.10 ± 0.30 | 0.78 ± 0.21 | 0.80 ± 0.21 | <0.01 | 0.71 |
| CMT (µm), mean ± SD | 570.98 ± 165.87 | 252.02 ± 17.43 | 257.00 ± 23.92 | <0.01 | 0.29 |
| SFCT (µm), mean ± SD | 265.28 ± 69.74 | 258.57 ± 66.36 | 264.66 ± 44.07 | 0.31 | 0.66 |
| Type (ischemia/nonischemia), n | 44/26 | NA | NA | NA | NA |
| RNP (mm2), mean ± SD | 42.59 ± 37.21 | NA | NA | NA | NA |
SE, spherical equivalent; D, diopter; ST, superotemporal; IT, inferotemporal; NA, not applicable.